Clinical Trials Directory

Trials / Unknown

UnknownNCT04354935

Treatment of Resistant Depression by Repetitive Transcranial Magnetic Stimulation (rTMS) Multicentric Naturalistic Study

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
160 (estimated)
Sponsor
Centre hospitalier de Ville-Evrard, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Repetitive Transcranial Magnetic Stimulation (rTMS) for repetitive Transcranial Magnetic Stimulation) is a a recent technique to stimulate the brain in a way that non-invasive, for therapeutic purposes. The first trials of analgesic use of rTMS date back to about 15 years ago. years and clinical use has now entered the practice of some specialized centers. Used at a frequency less than or equal to 1 Hertz (Hz; a stimulation per second), it is called bass rTMS. frequency and results in inhibition of cortical excitability at the level of the stimulated area. Conversely, a stimulation with a frequency higher than 5 Hz, called high-frequency rTMS, will have an excitatory effect on the targeted neurons. In addition to its local effects at the stimulation site, rTMS can also have effects on distance on regions other than those directly targeted. The impact of this treatment would be the local modulation of the cerebral plasticity and also act on the anatomical connectivity and functional brain function in both healthy subjects and those who are patients with psychiatric disorders

Detailed description

Main objective : To show the effectiveness of rTMS carried out in open on the symptoms of depression resistant in common practice between the Baseline and the end of the initial treatment (between 1 and 6 weeks). Secondary Objectives Evaluate the tolerance of the rTMS carried out in open on the symptoms of depression resistant in common practice between the Baseline and the end of the initial cure (between 1 and 6 weeks) Evaluate the impact of this treatment on : * The response rate * The remission rate * Quality of life To assess the correlation between personality dimensions and depression. The criteria main evaluation : The evolution of the HDRS-17 score (Hamilton depression scale, 17 items) between the Baseline and the end of the initial treatment (1 to 6 weeks) The evaluation criteria secondary : * Responder patient rate (defined as a 50% decrease in the rate of % of HDRS score) * Rate of patients in remission (defined by HDRS score\<8) * Evolution of the EQ5D quality of life score between Baseline and end of the initial treatment (between 1 and 6 weeks)

Conditions

Interventions

TypeNameDescription
DEVICErTMS basic1 session per day, for 4 or 6 weeks.
DEVICErTMS VIIT5 sessions per day, for 2 weeks.
DEVICErTMS SAINT modified8 sessions per day, for 1 week.
DEVICErTMS SAINT10 sessions per day, for 1 week.

Timeline

Start date
2019-10-18
Primary completion
2025-11-28
Completion
2026-02-28
First posted
2020-04-21
Last updated
2023-02-27

Locations

2 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04354935. Inclusion in this directory is not an endorsement.